Atria Investments Inc Has $1.56 Million Stock Position in Axon Enterprise, Inc. (NASDAQ:AXON)

Atria Investments Inc lifted its stake in Axon Enterprise, Inc. (NASDAQ:AXON) by 31.4% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,901 shares of the biotechnology company’s stock after acquiring an additional 933 shares during the period. Atria Investments Inc’s holdings in Axon Enterprise were worth $1,559,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the company. Vanguard Group Inc. boosted its stake in Axon Enterprise by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 8,143,306 shares of the biotechnology company’s stock valued at $2,547,878,000 after purchasing an additional 212,401 shares during the period. 1832 Asset Management L.P. raised its stake in Axon Enterprise by 44.0% during the second quarter. 1832 Asset Management L.P. now owns 375,700 shares of the biotechnology company’s stock worth $110,546,000 after acquiring an additional 114,800 shares in the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of Axon Enterprise by 13.9% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 368,732 shares of the biotechnology company’s stock worth $108,496,000 after purchasing an additional 45,049 shares in the last quarter. Thrivent Financial for Lutherans raised its stake in shares of Axon Enterprise by 1.6% in the second quarter. Thrivent Financial for Lutherans now owns 270,430 shares of the biotechnology company’s stock valued at $79,571,000 after acquiring an additional 4,365 shares during the last quarter. Finally, Federated Hermes Inc. boosted its stake in Axon Enterprise by 14.5% in the second quarter. Federated Hermes Inc. now owns 234,185 shares of the biotechnology company’s stock worth $68,907,000 after purchasing an additional 29,680 shares in the last quarter. 79.08% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on AXON shares. Needham & Company LLC increased their price target on shares of Axon Enterprise from $525.00 to $600.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Craig Hallum upped their target price on shares of Axon Enterprise from $370.00 to $376.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Robert W. Baird raised their price target on Axon Enterprise from $440.00 to $460.00 and gave the stock an “outperform” rating in a research report on Monday, November 4th. Barclays boosted their price objective on shares of Axon Enterprise from $381.00 to $387.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Finally, The Goldman Sachs Group raised their price target on shares of Axon Enterprise from $385.00 to $441.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, Axon Enterprise presently has a consensus rating of “Moderate Buy” and a consensus target price of $427.83.

Axon Enterprise Stock Down 0.9 %

AXON opened at $599.35 on Friday. The stock’s fifty day simple moving average is $438.79 and its 200 day simple moving average is $357.27. The company has a current ratio of 2.96, a quick ratio of 2.63 and a debt-to-equity ratio of 0.32. The stock has a market cap of $45.70 billion, a PE ratio of 154.87, a price-to-earnings-growth ratio of 15.10 and a beta of 0.94. Axon Enterprise, Inc. has a 1-year low of $220.78 and a 1-year high of $624.84.

Insider Activity at Axon Enterprise

In related news, President Joshua Isner sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $606.15, for a total transaction of $12,123,000.00. Following the completion of the transaction, the president now directly owns 208,166 shares in the company, valued at $126,179,820.90. This represents a 8.77 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of the business’s stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $373.03, for a total value of $167,863.50. Following the sale, the director now owns 7,379 shares in the company, valued at $2,752,588.37. This represents a 5.75 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 411,006 shares of company stock worth $161,360,618. Insiders own 6.10% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.